LEADER 01294nam 2200421 450 001 9910555269303321 005 20210318004132.0 010 $a1-119-65884-5 010 $a1-119-65885-3 010 $a1-119-65883-7 035 $a(CKB)4100000011689707 035 $a(MiAaPQ)EBC6437588 035 $a(EXLCZ)994100000011689707 100 $a20210318d2021 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAWS certified security study guide $especialty (SCS-C01) Exam /$fDario Lucas Goldfarb [and six others] 210 1$aIndianapolis, Indiana :$cJohn Wiley and Sons,$d[2021] 210 4$d©2021 215 $a1 online resource (494 pages) $cillustrations 300 $aIncludes index. 311 $a1-119-65881-0 606 $aCloud computing$xExaminations$vStudy guides 606 $aWeb services$xExaminations$vStudy guides 615 0$aCloud computing$xExaminations 615 0$aWeb services$xExaminations 676 $a004.6782 702 $aGoldfarb$b Dario Lucas 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910555269303321 996 $aAWS certified security study guide$92818059 997 $aUNINA LEADER 02207oam 2200649 450 001 9910715378403321 005 20210217085949.0 035 $a(CKB)5470000002510248 035 $a(OCoLC)765493529$z(OCoLC)123561201$z(OCoLC)645416460$z(OCoLC)827206542 035 $a(EXLCZ)995470000002510248 100 $a20111201d2000 ua 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aEffects of NIBRS on crime statistics /$fby Ramona R. Rantala ; with technical support from Thomas J. Edwards 205 $a[Corrected edition]. 210 1$a[Washington, D.C.] :$cU.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics,$d2000. 215 $a1 online resource (15 pages) $cillustrations 225 1 $aBureau of Justice Statistics, Special report 300 $a"July 2000." 300 $a"NCJ 178890." 320 $aIncludes bibliographical references. 517 3 $aEffects of National Incident-Based Reporting System on crime statistics 606 $aCriminal statistics$zUnited States 606 $aCrime analysis$zUnited States$xStatistical methods 606 $aCriminal records$zUnited States$xStatistical methods 606 $aCrime analysis$xStatistical methods$2fast 606 $aCriminal statistics$2fast 607 $aUnited States$2fast 615 0$aCriminal statistics 615 0$aCrime analysis$xStatistical methods. 615 0$aCriminal records$xStatistical methods. 615 7$aCrime analysis$xStatistical methods. 615 7$aCriminal statistics. 700 $aRantala$b Ramona R.$01404238 701 $aEdwards$b Thomas J$01410610 712 02$aUnited States.$bBureau of Justice Statistics, 801 0$bOCLCE 801 1$bOCLCE 801 2$bNLL 801 2$bOCLCQ 801 2$bOCLCO 801 2$bOCLCA 801 2$bBUF 801 2$bOCLCQ 801 2$bOCLCO 801 2$bOCLCA 801 2$bOCLCQ 801 2$bOCLCF 801 2$bOCLCQ 801 2$bGPO 906 $aBOOK 912 $a9910715378403321 996 $aEffects of NIBRS on crime statistics$93499710 997 $aUNINA LEADER 01541nas 2200373 n 450 001 990008937560403321 005 20240229084434.0 011 $a0142-8047 035 $a000893756 035 $aFED01000893756 035 $a(Aleph)000893756FED01 035 $a000893756 091 $2CNR$aP 00020649 100 $a20161109a19679999km-y0itaa50------ba 101 0 $aeng 102 $aGB 110 $aauu-------- 200 1 $aCell membranes 207 1$a1967- 210 $aSheffield$cUniversity of Sheffield Biomedical Information Service 530 0 $aCell membranes 675 $a576.314 676 $a016.574875 712 02$aUniversity of Sheffield$bBiomedical Information Service 801 0$aIT$bACNP$c20090723 859 4 $uhttp://acnp.cib.unibo.it/cgi-ser/start/it/cnr/dc-p1.tcl?catno=12431&person=false&language=ITALIANO&libr=&libr_th=unina1$zBiblioteche che possiedono il periodico 901 $aSE 912 $a990008937560403321 958 $aBiblioteca del Dipartimento di Pediatria dell'Universitą degli Studi di Napoli Federico II$b1979-1982;$fDMEPE 959 $aDMEPE 996 $aCell membranes$9796782 997 $aUNINA AP1 8 $6866-01$aNA171 Biblioteca del Dipartimento di Pediatria dell'Universitą degli Studi di Napoli Federico II$evia Pansini, 5, 80131 Napoli (NA)$m0817463384;$m0817463384$nit AP2 40$aacnp.cib.unibo.it$nACNP Italian Union Catalogue of Serials$uhttp://acnp.cib.unibo.it/cgi-ser/start/it/cnr/df-p.tcl?catno=12431&language=ITALIANO&libr=&person=&B=1&libr_th=unina&proposto=NO LEADER 03808nam 22004455 450 001 9910303443003321 005 20251116212906.0 010 $a3-030-02505-5 024 7 $a10.1007/978-3-030-02505-2 035 $a(PPN)232960534 035 $a(CKB)4100000007204825 035 $a(MiAaPQ)EBC5614210 035 $a(DE-He213)978-3-030-02505-2 035 $a(EXLCZ)994100000007204825 100 $a20181211d2018 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aImmunotherapy /$fedited by Aung Naing, Joud Hajjar 205 $a2nd ed. 2018. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018. 215 $a1 online resource (183 pages) 225 1 $aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v995 311 08$a3-030-02504-7 327 $aOverview of Basic Immunology and Translational Relevance for Clinical Investigators -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: A New Age in cancer treatment -- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice -- Skin Reactions to Immune Checkpoint Inhibitors -- Immune-related Adverse Events: Pneumonitis -- Immune checkpoint inhibitors-induced colitis -- Immune checkpoint inhibitors-induced hepatitis -- Symptoms as patient-reported outcomes in cancer patients undergoing immunotherapies . 330 $aThe second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions. Edited by two renowned experts in the field, the book?s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science. 410 0$aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v995 606 $aOncology 606 $aCancer Research$3http://scigraph.springernature.com/things/product-market-codes/B11001 615 0$aOncology. 615 14$aCancer Research. 676 $a616.9046 702 $aNaing$b Aung$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aHajjar$b Joud$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910303443003321 996 $aImmunotherapy$92019290 997 $aUNINA